


Clinical Trials Innovation

- How much effort does your team spend finding and comparing similar trials to optimize study design?
- Are you confident that your trial criteria maximize recruitment without unnecessary exclusions?
- How do you use real-world evidence to align trial design with actual patient populations?
- What challenges arise in justifying trial designs to regulators using historical data?
- How do you track competitor trial strategies, and how often do you reassess designs based on trends?

Answering these questions emphasizes the importance of clinical trials in drug development. AI can enhance and speed up trial design and startup activities by automating candidate identification, qualification, and competitor trial analysis. Research teams must distill accurate, up-to-date information by navigating vast content from clinical registries, scientific publications, and real-world data.

Trial Candidate Identification



Patient recruitment is crucial for clinical trial design and success. Hybrid AI agents can process millions of records, extract real-world data from unstructured data sources, create patient profiles, and identify site locations. By matching trial protocol requirements with real-world evidence, AI provides insights to optimize eligibility criteria, reduce timeline risks, and accelerate patient enrollment.

Apply inclusion criteria that the targeted patient population must qualify for, such as:

- demographics
- clinical characteristics
- duration of disease
- severity of disease


Implement exclusion criteria that may interfere with the study or increase the risk of an unfavorable outcome or adverse events, such as:

- comorbidities
- disease stage
- current treatment methods

Competitive Intelligence

The imperative for rapid innovation in pharma fuels evolving treatments to keep the pipeline rich and drives fierce competition in the industry. This in turn requires keeping a close watch on the competition with a robust pharma competitive intelligence strategy that includes the monitoring of trials and scientific literature sources for insights into ongoing drug developments.

Expert.ai's technology mines data from more than 900,000+ clinical trials worldwide. This includes clinical trial registries such as



clinicaltrials.gov, EUDRA, EUPAS, Asian and Australian registries, and others. It provides the most up-to-date and comprehensive data landscape by disease, drug, mechanisms of action, organization, or geography. Not only can researchers find related trials, but they can also access related publications, news, study results and principal investigators all in one place.

Put expert.ai for Clinical Trials Innovation to work

- **Data Indexing & Classification**
Organize, classify, and filter public data, publications, and clinical trial to extract insights on a targeted disease.
- **Eligibility Criteria Matching**
Classify trials by inclusion/exclusion criteria to efficiently map patients or trial designs to relevant research.
- **AI-Powered Information Retrieval & Reasoning**
Use conversational AI to answer research questions instantly by integrating structured data and literature.
- **Agentic AI for Continuous Learning & Insights**
Continuously monitor and integrate new scientific data while tracking evolving insights with adaptive learning.

Benefits from AI-driven Clinical Trials Innovation

- Faster & more accurate clinical trial comparisons
- Optimized eligibility criteria for improved recruitment
- Real-world evidence integration for more representative trials
- AI-Driven regulatory & evidence-based trial justifications
- Competitive intelligence & dynamic trial strategy adjustments

About us

Expert.ai (EXAI:IM) leverages more than 30 years of AI expertise to transform Pharma and Healthcare. Our advanced hybrid AI capabilities empower researchers, clinicians, and pharmaceutical leaders to extract insights from complex medical data, accelerating drug discovery, optimizing clinical trials, and enhancing real-world evidence analysis for smarter, data-driven decisions.